ABUS is expected to report earnings to fall 33.33% to -1 cents per share on November 11
Q3'26
Est.
$-0.02
Q2'26
Est.
$-0.03
Q1'26
Beat
by $0.91
Q4'25
Missed
by $0.14
Q3'25
Missed
by $0.01
The last earnings report on August 12 showed earnings per share of -2 cents, meeting the estimate of -2 cents. With 12.59M shares outstanding, the current market capitalization sits at 1.03B.
A.I. Advisor
published General Information
General Information
a developer of drugs to improve the treatment of cancer
A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with ARRY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then ARRY could also see price increases.
ABUS saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for ABUS moved out of overbought territory on August 21, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 54 similar instances where the indicator exited the overbought zone. In of the 54 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ABUS broke above its upper Bollinger Band on August 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 05, 2026. You may want to consider a long position or call options on ABUS as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ABUS just turned positive on August 06, 2026. Looking at past instances where ABUS's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
ABUS moved above its 50-day moving average on August 05, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABUS crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in of 252 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 216 cases where ABUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.984) is normal, around the industry mean (20.145). P/E Ratio (6.595) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.574) is also within normal values, averaging (444.692).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
